相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines
Jane Moseley et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
PDG69 Assessing the VALUE of Nice HTA Scientific Advice on the Products Appraised By Nice: A Retrospective 10 Year Study
F. Maignen et al.
VALUE IN HEALTH (2020)
Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
Ting Wang et al.
FRONTIERS IN PHARMACOLOGY (2020)
European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective
Saima Khan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations
Giovanni Tafuri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY
Charalabos-Markos Dintsios et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2018)
Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions
Ting Wang et al.
VALUE IN HEALTH (2018)
EARLY DIALOGUE IN EUROPE: PERSPECTIVES ON VALUE, CHALLENGES, AND CONTINUING EVOLUTION
Lina Balaisyte et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2018)
A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
Nicola Allen et al.
FRONTIERS IN PHARMACOLOGY (2017)
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice
Giovanni Tafuri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
G-BA EARLY ADVICE VS. EMA/HTA PARALLEL ADVICE FROM A GERMAN PERSPECTIVE
K. Wiebe et al.
VALUE IN HEALTH (2016)
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
Michael Ermisch et al.
Frontiers in Pharmacology (2016)
REGULATORY WATCH Impact of scientific advice from the European Medicines Agency
Matthias P. Hofer et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
EMA's parallel advice workshop bridges regulatory and reimbursement divide
Suzanne Elvidge
NATURE REVIEWS DRUG DISCOVERY (2014)
A company experience of the first MoCA pilot project
Wills Hughes-Wilson
Orphanet Journal of Rare Diseases (2014)
TRENDS IN EARLY ENGAGEMENT BETWEEN INDUSTRY AND HTA : ANALYSIS OF SCIENTIFIC ADVICE SERVICE PROVIDED BY NICE SINCE 2009
F. M. Maignen et al.
VALUE IN HEALTH (2014)
Early Scientific Advice Obtained Simultaneously from Regulators and Payers: Findings from a Pilot Study in Australia
Michael Wonder et al.
VALUE IN HEALTH (2013)
Health economics and outcomes research within drug development
Floortje van Nooten et al.
DRUG DISCOVERY TODAY (2012)
INTERACTIONS INITATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY
Katrine Fronsdal et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2012)
Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities
Chris Henshall et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
Involving stakeholders and developing a policy for stakeholder involvement in the European network for Health Technology Assessment, EUnetHTA
Camilla Palmhoj Nielsen et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
分享论文
